Korlym FDA Approval History
FDA Approved: Yes (First approved February 17, 2012)
Brand name: Korlym
Generic name: mifepristone
Dosage form: Tablets
Company: Corcept Therapeutics
Treatment for: Cushing's Syndrome
Korlym (mifepristone) is a cortisol receptor blocker indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance.
Development timeline for Korlym
|Feb 17, 2012||Approval FDA Approves Korlym for Patients with Endogenous Cushing's Syndrome|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.